BEAM

BEAM INC COM STK (DE)

BEAM

Delisted

BEAM was delisted on the 30th of April, 2014.

Back to rankings

Consumer Staples Beverages - Non-Alcoholic

Financial journalist opinion

Zacks Investment Research

CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?

CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.

CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m.

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Zacks Investment Research

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

Zacks Investment Research

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.11 per share a year ago.

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Zacks Investment Research

Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know

Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know

Zacks Investment Research

Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?

Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?

The Motley Fool

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Zacks Investment Research

3 Promising Genomics Stocks to Keep an Eye On in 2025

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

3 Promising Genomics Stocks to Keep an Eye On in 2025

See News Rankings

Charts implemented using Lightweight Charts™